Eli Lilly: A Heavyweight Battle Isn't Won In Round 1 [Seeking Alpha]
Eli Lilly and Company (LLY)
Last eli lilly and company earnings: 4/23 06:25 am
Check Earnings Report
US:NYSE Investor Relations:
investor.lilly.com
Company Research
Source: Seeking Alpha
LLY's long-term advantage lies in small molecule manufacturing economics, Zepbound switcher potential, and durable gross margin prospects. My updated DCF analysis values LLY at $970.83/share, about 10% above current levels, supporting a continued 'Buy' rating. Key risks include Foundayo underperformance, Medicare coverage setbacks, pricing erosion, and execution risks, but risk/reward skews favorably into Q1 earnings. greenleaf123/iStock via Getty Images Overview I'm previewing Eli Lilly and Company's ( LLY ) Q1 earnings that are expected to be announced at the end of the month, April 30. Now, I'm going to view this through the lens of a “heavyweight battle” between Eli Lilly and Novo Nordisk ( This article is intended to provide informational content and should not be viewed as an exhaustive analysis of the featured company. It should not be interpreted as personalized investment advice with regard to "Buy/Sell/Hold/Short/Long" recommendations. Financial models presented
Show less
Read more
Impact Snapshot
Event Time:
LLY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LLY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LLY alerts
High impacting Eli Lilly and Company news events
Weekly update
A roundup of the hottest topics
LLY
News
- Why Eli Lilly Stock Flopped on Friday [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
- Why Eli Lilly Stock Flopped on Friday [Yahoo! Finance]Yahoo! Finance
- Eli Lilly Stock Falls. Novo Extends Lead in Weight-Loss Drug Race [Yahoo! Finance]Yahoo! Finance
- Eli Lilly's new GLP-1 pill vs. Wegovy, JPMorgan initiates coverage on Hims [Yahoo! Finance]Yahoo! Finance
- Eli Lilly Shares Dip Despite Stable Growth in GLP-1 Prescriptions [Yahoo! Finance]Yahoo! Finance
LLY
Earnings
- 2/4/26 - Beat
LLY
Sec Filings
- 4/21/26 - Form 4
- 4/21/26 - Form 4
- 4/21/26 - Form 4
- LLY's page on the SEC website